Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

PA Francis; GF Fleming; I Láng; EM Ciruelos; HR Bonnefoi; M Bellet; A Bernardo; MA Climent; S Martino; B Bermejo; HJ Burstein; NE Davidson; CE Geyer; BA Walley; JN Ingle; RE Coleman; B Müller; F Le Du; S Loibl; EP Winer; B Ruepp; S Loi; M Colleoni; AS Coates; RD Gelber; A Goldhirsch; MM Regan

Journal article

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

PA Francis, GF Fleming, I Láng, EM Ciruelos, HR Bonnefoi, M Bellet, A Bernardo, MA Climent, S Martino, B Bermejo, HJ Burstein, NE Davidson, CE Geyer, BA Walley, JN Ingle, RE Coleman, B Müller, F Le Du, S Loibl, EP Winer Show all

Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2023

DOI: 10.1200/JCO.22.01065

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The Suppression of Ovarian Function Trial (SOFT; ClinicalTrials.gov identifier: NCT00066690) randomly assigned premenopausal women with hormone receptor-positive breast cancer to 5 years of adjuvant tamoxifen, tamoxifen plus ovarian function suppression (OFS), or exemestane plu..

View full abstract

University of Melbourne Researchers

Prudence A. Francis Author

Sherene Loi Author

Related Projects (1)

2018 NBCF ENDOWED CHAIR PROGRAM

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

Supported by Breast Cancer Trials Australia and New Zealand (National Health and Medical Research Council grant Nos. 351161, 510788 and 1105058); Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) on behalf of the National Cancer Research Institute Breast Clinical Studies Group, United Kingdom (NCRI-BCSG-ICR-CTSU Partnership); Cancer Research UK grant Nos. CRUKE/03/022, CRUKE/03/023, and C1491/A15955; National Institute for Health Research Royal Marsden/Institute of Cancer Research Biomedical Research Centre (no grant No.); and National Institute for Health Research/Cambridge Biomedical Research Centre (no grant No.); Alliance for Clinical Trials in Oncology (US NIH grant No. U10CA180821); SWOG (US NIH grant Nos. U10CA180888, UG1CA233160, and UG1CA233329); ECOG-ACRIN Cancer Research Group (US National Institutes of Health [NIH] grant Nos. U10CA180820 and U10CA180794); NRG Oncology (US NIH grant Nos. U10CA180868, U10CA180822, and UG1CA189867); Canadian Cancer Trials Group (US NIH grant No. U10CA180863, and Canadian Cancer Society grant No. 707213). SOFT is sponsored by the ETOP IBCSG Partners Foundation. Conduct is supported by the ETOP IBCSG Partners Foundation, which has included additional support for the IBCSG from the Frontier Science Foundation, Swiss Group for Clinical Cancer Research Switzerland, Oncosuisse, Cancer League Switzerland, Foundation for Clinical Cancer Research of Eastern Switzerland (grant No. U24 CA075362 from the US NCI). Longer-term follow-up of SOFT has been supported also by grants to the IBCSG from Pfizer (WI223438), Ipsen, Debiopharm, TerSera, AstraZeneca (57735423), the Breast Cancer Research Foundation (16-185,17-187,18-003,19-011,20-011,21-011) and private donors. SOFT conduct in the US and Canada have been supported by US NCI NCTN via the Alliance for Clinical Trials in Oncology (grant Nos. above).